UA92761C2 - Кристаллы лаквинимода натрия и способ их изготовления - Google Patents
Кристаллы лаквинимода натрия и способ их изготовленияInfo
- Publication number
- UA92761C2 UA92761C2 UAA200806003A UAA200806003A UA92761C2 UA 92761 C2 UA92761 C2 UA 92761C2 UA A200806003 A UAA200806003 A UA A200806003A UA A200806003 A UAA200806003 A UA A200806003A UA 92761 C2 UA92761 C2 UA 92761C2
- Authority
- UA
- Ukraine
- Prior art keywords
- smarttagscrystalsof
- schemas
- urn
- microsoft
- com
- Prior art date
Links
- 229960004577 laquinimod Drugs 0.000 title abstract 2
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000013078 crystal Substances 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000012535 impurity Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72865705P | 2005-10-19 | 2005-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA92761C2 true UA92761C2 (ru) | 2010-12-10 |
Family
ID=37963287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200806003A UA92761C2 (ru) | 2005-10-19 | 2006-10-18 | Кристаллы лаквинимода натрия и способ их изготовления |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US7884208B2 (enExample) |
| EP (2) | EP2687512A1 (enExample) |
| JP (3) | JP5832716B2 (enExample) |
| KR (1) | KR101440982B1 (enExample) |
| CN (3) | CN101291911B (enExample) |
| AR (1) | AR056708A1 (enExample) |
| AU (1) | AU2006304672B2 (enExample) |
| BR (1) | BRPI0617477A2 (enExample) |
| CA (1) | CA2625287C (enExample) |
| DK (1) | DK1937642T3 (enExample) |
| ES (1) | ES2523762T3 (enExample) |
| HR (1) | HRP20141160T1 (enExample) |
| IL (1) | IL190137A (enExample) |
| NZ (2) | NZ592897A (enExample) |
| PL (1) | PL1937642T3 (enExample) |
| PT (1) | PT1937642E (enExample) |
| RS (1) | RS53666B1 (enExample) |
| RU (1) | RU2415841C2 (enExample) |
| SG (1) | SG10201508623RA (enExample) |
| SI (1) | SI1937642T1 (enExample) |
| UA (1) | UA92761C2 (enExample) |
| WO (1) | WO2007047863A2 (enExample) |
| ZA (1) | ZA200803527B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| SI1937642T1 (sl) * | 2005-10-19 | 2015-01-30 | Teva Pharmaceutical Industries Ltd. | Kristali natrijevega lakvinimoda in postopek za njihovo pripravo |
| HRP20120093T1 (hr) * | 2006-06-12 | 2012-03-31 | Teva Pharmaceutical Industries Limited | Postojani pripravci lakvinimoda |
| SI2234485T1 (sl) | 2007-12-20 | 2014-03-31 | Teva Pharmaceutical Industries Ltd. | Stabilni lakvinimodni pripravki |
| EP2318371A2 (en) | 2008-07-01 | 2011-05-11 | Actavis Group PTC EHF | Novel solid state forms of laquinimod and its sodium salt |
| EA021227B1 (ru) * | 2008-09-03 | 2015-05-29 | Тева Фармасьютикал Индастриз Лтд. | 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции |
| US20120009226A1 (en) | 2008-12-17 | 2012-01-12 | Actavis Group Ptc Ehf | Highly pure laquinimod or a pharmaceutically acceptable salt thereof |
| DE102009008851A1 (de) | 2009-02-13 | 2010-08-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
| DE102010048788A1 (de) | 2009-02-13 | 2011-05-19 | Amw Gmbh | Transdermales System mit Immunmodulator |
| US20100322900A1 (en) | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with laquinimod |
| US8598203B2 (en) * | 2009-07-30 | 2013-12-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of Crohn's disease with laquinimod |
| CA2771203C (en) | 2009-08-10 | 2019-04-09 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| DE102010026879A1 (de) | 2010-02-11 | 2011-08-11 | AMW GmbH, 83627 | Transdermales System mit Immunmodulator |
| ES2558556T3 (es) * | 2010-03-03 | 2016-02-05 | Teva Pharmaceutical Industries Ltd. | Tratamiento de nefritis lúpica usando laquinimod |
| JP2013521305A (ja) * | 2010-03-03 | 2013-06-10 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドを用いるループス関節炎の治療 |
| BR112012022187A2 (pt) * | 2010-03-03 | 2015-09-22 | Teva Pharma | tratamento de artrite reumatóide com a combinação de laquinimod e metotrexato |
| EP2590653A4 (en) | 2010-07-09 | 2014-01-01 | Teva Pharma | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF |
| PE20130396A1 (es) | 2010-07-09 | 2013-04-19 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma |
| IN2013MN00811A (enExample) | 2010-11-28 | 2015-06-12 | Mapi Pharma Ltd | |
| CN106344576A (zh) * | 2011-10-12 | 2017-01-25 | 泰华制药工业有限公司 | 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症 |
| TW201345527A (zh) | 2012-02-03 | 2013-11-16 | Teva Pharma | 拉喹莫德於治療對第一線抗－ＴＮＦα療法無效之克隆氏症患者之用途 |
| AR090073A1 (es) | 2012-02-16 | 2014-10-15 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos |
| US20130259856A1 (en) | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| AR091706A1 (es) * | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| CN103626701A (zh) * | 2012-08-28 | 2014-03-12 | 天津药物研究院 | 一种制备喹啉衍生物的方法 |
| CN103626702A (zh) * | 2012-08-30 | 2014-03-12 | 天津药物研究院 | 一种制备喹啉酮衍生物的方法 |
| CN104584098B (zh) | 2012-09-03 | 2017-09-15 | 丰田自动车株式会社 | 碰撞判定装置和碰撞判定方法 |
| HK1215210A1 (zh) | 2012-11-07 | 2016-08-19 | Teva Pharmaceutical Industries Ltd. | 拉喹莫德胺盐 |
| EA201591699A1 (ru) * | 2013-03-14 | 2016-02-29 | Тева Фармасьютикал Индастриз Лтд. | Кристаллы лаквинимода натрия и улучшенный способ их производства |
| WO2014152009A1 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Transdermal formulations of laquinimod |
| CN114890943A (zh) | 2013-11-15 | 2022-08-12 | 阿克比治疗有限公司 | {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸固体形式，组合物和用途 |
| US20150306088A1 (en) | 2014-04-29 | 2015-10-29 | Teva Pharmaceutical Industries, Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| JP2022130270A (ja) * | 2021-02-25 | 2022-09-06 | シンバイオシス株式会社 | 腸管吸収用補助剤及びその利用方法 |
| KR102876408B1 (ko) * | 2022-01-24 | 2025-10-24 | 한국과학기술원 | 입도가 조절된 헥사나이트로스틸벤 타입 iv의 제조방법 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US613574A (en) * | 1898-11-01 | Feed-regulator | ||
| US3024257A (en) * | 1961-04-10 | 1962-03-06 | Frosst & Co Charles E | Stable preparations of alkali metal salts of estrone sulfate |
| FR2340735A1 (fr) * | 1976-02-11 | 1977-09-09 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
| IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| DE3437232A1 (de) * | 1984-10-10 | 1986-04-17 | Mack Chem Pharm | Stabilisierte injektionsloesungen von piroxicam |
| SE8902076D0 (sv) | 1989-06-09 | 1989-06-09 | Pharmacia Ab | Derivatives of quinoline-3-carboxanilide |
| HUT60458A (en) | 1991-02-01 | 1992-09-28 | Sandoz Ag | Process for producing benzyloxyphenyl derivatives and pharmaceutical compositions comprising same |
| DE4120646A1 (de) * | 1991-06-22 | 1992-12-24 | Bayer Ag | 7-isoindolinyl-chinolon- und naphthyridoncarbonsaeure-derivate |
| US5540934A (en) * | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
| CH687615A5 (de) | 1994-09-07 | 1997-01-15 | R W Johnson Pharmaceutical Res | Tropen-Verpackung. |
| US5912349A (en) * | 1997-01-31 | 1999-06-15 | Pharmacia & Upjohn Company | Process for the preparation of roquinimex |
| US20030124187A1 (en) * | 1997-02-14 | 2003-07-03 | Smithkline Beecham Laboratoires Pharmaceutiques, | Pharmaceutical formulations comprising amoxycillin and clavulanate |
| US6256814B1 (en) | 1997-09-19 | 2001-07-10 | Cosco Management, Inc. | Playyard |
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| US6133285A (en) * | 1998-07-15 | 2000-10-17 | Active Biotech Ab | Quinoline derivatives |
| US6121287A (en) * | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE9802550D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| BR0011347A (pt) | 1999-06-07 | 2002-03-19 | Byk Gulden Lomberg Chem Fab | Preparações e formas de administração compreendendo um composto ativo de ácido instável |
| CN100390148C (zh) * | 1999-10-25 | 2008-05-28 | 活跃生物技术有限公司 | 用于治疗恶性肿瘤的药物 |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| JP2002031610A (ja) | 2000-07-14 | 2002-01-31 | Ajinomoto Co Inc | 生体分子複合体の界面残基を同定する方法 |
| US6307050B1 (en) * | 2000-08-29 | 2001-10-23 | R. T. Alamo Venture I Llc | Method of synthesizing flosequinan from 4-fluoroanthranilic acid |
| US6802422B2 (en) * | 2000-12-12 | 2004-10-12 | Multi-Comp, Inc. | Sealed blister assembly |
| US6706733B2 (en) * | 2001-05-08 | 2004-03-16 | Dainippon Ink And Chemicals, Inc. | Quinolinone derivative formulation and its production method |
| US20030119826A1 (en) * | 2001-09-24 | 2003-06-26 | Pharmacia Corporation | Neuroprotective treatment methods using selective iNOS inhibitors |
| SE0201778D0 (sv) * | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US7560557B2 (en) * | 2002-06-12 | 2009-07-14 | Active Biotech Ag | Process for the manufacture of quinoline derivatives |
| US6875869B2 (en) | 2002-06-12 | 2005-04-05 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| EP1386926A1 (en) | 2002-07-29 | 2004-02-04 | Bioxtal | Methods for producing labelled recombinant polypeptides and uses thereof |
| ITMI20021726A1 (it) | 2002-08-01 | 2004-02-02 | Zambon Spa | Macrolidi ad attivita' antiinfiammatoria. |
| US7820145B2 (en) * | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7790197B2 (en) * | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) * | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
| AU2003300692A1 (en) | 2003-10-30 | 2005-05-19 | Lupin Ltd. | Stable formulations of ace inhibitors and methods for preparation thereof |
| US8314124B2 (en) * | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| SI1937642T1 (sl) | 2005-10-19 | 2015-01-30 | Teva Pharmaceutical Industries Ltd. | Kristali natrijevega lakvinimoda in postopek za njihovo pripravo |
| HRP20120093T1 (hr) | 2006-06-12 | 2012-03-31 | Teva Pharmaceutical Industries Limited | Postojani pripravci lakvinimoda |
| SI2234485T1 (sl) | 2007-12-20 | 2014-03-31 | Teva Pharmaceutical Industries Ltd. | Stabilni lakvinimodni pripravki |
| EP2318371A2 (en) | 2008-07-01 | 2011-05-11 | Actavis Group PTC EHF | Novel solid state forms of laquinimod and its sodium salt |
| EA021227B1 (ru) * | 2008-09-03 | 2015-05-29 | Тева Фармасьютикал Индастриз Лтд. | 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции |
| US20100322900A1 (en) * | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with laquinimod |
| US8598203B2 (en) | 2009-07-30 | 2013-12-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of Crohn's disease with laquinimod |
| CA2771203C (en) * | 2009-08-10 | 2019-04-09 | Teva Pharmaceutical Industries Ltd. | Treatment of bdnf-related disorders using laquinimod |
| ES2558556T3 (es) * | 2010-03-03 | 2016-02-05 | Teva Pharmaceutical Industries Ltd. | Tratamiento de nefritis lúpica usando laquinimod |
| BR112012022187A2 (pt) * | 2010-03-03 | 2015-09-22 | Teva Pharma | tratamento de artrite reumatóide com a combinação de laquinimod e metotrexato |
| JP2013521305A (ja) * | 2010-03-03 | 2013-06-10 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドを用いるループス関節炎の治療 |
| PE20130396A1 (es) | 2010-07-09 | 2013-04-19 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma |
| EP2590653A4 (en) | 2010-07-09 | 2014-01-01 | Teva Pharma | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROCHINOLINE-3-CARBOXAMIDE, SALT THEREOF AND APPLICATIONS THEREOF |
| US20120055072A1 (en) * | 2010-09-08 | 2012-03-08 | Rankin Sammy D | Directional guide for fishing lures |
| MX2013006464A (es) * | 2010-12-07 | 2013-07-29 | Teva Pharma | Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple. |
-
2006
- 2006-10-18 SI SI200631860T patent/SI1937642T1/sl unknown
- 2006-10-18 CN CN200680039201.6A patent/CN101291911B/zh not_active Expired - Fee Related
- 2006-10-18 EP EP13153698.9A patent/EP2687512A1/en not_active Withdrawn
- 2006-10-18 BR BRPI0617477-9A patent/BRPI0617477A2/pt not_active Application Discontinuation
- 2006-10-18 NZ NZ592897A patent/NZ592897A/xx unknown
- 2006-10-18 US US11/583,282 patent/US7884208B2/en not_active Expired - Fee Related
- 2006-10-18 NZ NZ567088A patent/NZ567088A/en unknown
- 2006-10-18 CN CN2013102471796A patent/CN103333107A/zh active Pending
- 2006-10-18 RS RS20140629A patent/RS53666B1/sr unknown
- 2006-10-18 ZA ZA200803527A patent/ZA200803527B/xx unknown
- 2006-10-18 HR HRP20141160TT patent/HRP20141160T1/hr unknown
- 2006-10-18 SG SG10201508623RA patent/SG10201508623RA/en unknown
- 2006-10-18 EP EP06826297.1A patent/EP1937642B1/en active Active
- 2006-10-18 JP JP2008536806A patent/JP5832716B2/ja not_active Expired - Fee Related
- 2006-10-18 DK DK06826297.1T patent/DK1937642T3/en active
- 2006-10-18 WO PCT/US2006/040925 patent/WO2007047863A2/en not_active Ceased
- 2006-10-18 PT PT68262971T patent/PT1937642E/pt unknown
- 2006-10-18 PL PL06826297T patent/PL1937642T3/pl unknown
- 2006-10-18 RU RU2008119456/04A patent/RU2415841C2/ru not_active IP Right Cessation
- 2006-10-18 UA UAA200806003A patent/UA92761C2/ru unknown
- 2006-10-18 CA CA2625287A patent/CA2625287C/en not_active Expired - Fee Related
- 2006-10-18 AU AU2006304672A patent/AU2006304672B2/en not_active Ceased
- 2006-10-18 ES ES06826297.1T patent/ES2523762T3/es active Active
- 2006-10-18 KR KR1020087011727A patent/KR101440982B1/ko not_active Expired - Fee Related
- 2006-10-18 CN CN201710533188.XA patent/CN107176923A/zh active Pending
- 2006-10-19 AR ARP060104574A patent/AR056708A1/es unknown
-
2008
- 2008-03-13 IL IL190137A patent/IL190137A/en not_active IP Right Cessation
-
2011
- 2011-01-21 US US13/011,233 patent/US8647646B2/en not_active Expired - Fee Related
- 2011-01-21 US US13/011,187 patent/US8673322B2/en not_active Expired - Fee Related
-
2012
- 2012-12-19 JP JP2012277069A patent/JP2013100299A/ja not_active Withdrawn
-
2014
- 2014-02-20 US US14/185,470 patent/US20140171647A1/en not_active Abandoned
-
2015
- 2015-07-31 JP JP2015152209A patent/JP2016020353A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA92761C2 (ru) | Кристаллы лаквинимода натрия и способ их изготовления | |
| TW200517393A (en) | Processes for the preparation of benzoimidazole derivatives | |
| SI1592401T1 (sl) | Postopek za modificiranje zdravilne kristalne oblike mikofenola natrijeve soli | |
| TW200420541A (en) | Crystalline forms | |
| WO2006024024A3 (en) | Solid and crystalline ibandronate sodium and processes for preparation thereof | |
| WO2010001257A3 (en) | Novel solid state forms of laquinimod and its sodium salt | |
| PT1656381E (pt) | Cristalização de formas sólidas de sais de adição de clopidogrel | |
| IL183104A0 (en) | Method for production of candesartan | |
| ZA200800138B (en) | Process for the preparation of crystalline perindopril | |
| WO2009021943A3 (de) | Neues herstellverfahren | |
| EP1883619A4 (en) | PROCESS FOR THE PREPARATION OF SUBSTITUTED TETRAFLUOROBENZYLANILINE COMPOUND AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | |
| WO2006066044A3 (en) | Processes for producing 4-aminoquinazolines | |
| WO2008059518A3 (en) | Process for preparing crystalline aripiprazole | |
| AU2003237598A8 (en) | Process for the preparation of highly pure rabeprazole sodium salt | |
| WO2006053625A8 (en) | Crystalline form of cefdinir ammonium salt as an intermediate for the preparation of pure cefdinir | |
| WO2007013043A3 (en) | Processes for the preparation of 7-amino-3-vinyl cephalosporanic acid | |
| MX2010002300A (es) | Polimorfos de sal sodica del acido (3-(((4-terc-butil-bencil)-(pir idin-3-sulfonil)-amino)-metil)-fenoxi)-acetico o un hidrato de los mismos y procedimientos para fabricar los mismos. | |
| WO2004078107A3 (fr) | Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables | |
| HUP0402634A2 (en) | Process for producing meloxicam and meloxicam potassium salt of high purity | |
| WO2007052296A3 (en) | A process of preparing amorphous atorvastatin calcium | |
| EP1831171A4 (en) | PROCESS FOR THE PREPARATION OF NEW MONTELUKAST SODIUM AMORPHOUS | |
| WO2008022962A3 (de) | Verfahren zur herstellung von n-piperidinyl-benzodiazepinen mit cgrp-antagonistischen eigenschaften | |
| EP1828214A4 (en) | PROCESS FOR THE SYNTHESIS OF A PURE POLYMORPHIC FORM OF SODIUM 3-PYRIDYL-1-HYDROXYETHYLIDINE-1,1-BISPHOSPHONATE | |
| MX2007004400A (es) | Procedimiento para la preparacion de n-(3,5-dicloropirid-a-il)-4- ifluorometoxi-8-metanosulfonamido-dibenzo [b,d] difuran-1-carboxamida. | |
| CY1115888T1 (el) | Κρυσταλλοι του laquinimod sodium και διαδικασια για την κατασκευη αυτων |